On August 31, 2020, Hochhaus, Andreas; Gambacorti-Passerini, Carlo; Abboud, Camille; Gjertsen, Bjoern Tore; Bruemmendorf, Tim H.; Smith, B. Douglas; Ernst, Thomas; Giraldo-Castellano, Pilar; Olsson-Stroemberg, Ulla; Saussele, Susanne; Bardy-Bouxin, Nathalie; Viqueira, Andrea; Leip, Eric; Russell-Smith, T. Alexander; Leone, Jocelyn; Rosti, Gianantonio; Watts, Justin; Giles, Francis J.; on behalf of the BYOND Study Investigators published an article.Recommanded Product: 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile The title of the article was Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study. And the article contained the following:
Bosutinib is approved for newly diagnosed Philadelphia chromosome-pos. (Ph+) chronic phase (CP) chronic myeloid leukemia (CML) and for Ph+ CP, accelerated (AP), or blast (BP) phase CML after prior treatment with tyrosine kinase inhibitors (TKIs). In the ongoing phase 4 BYOND study (NCT02228382), 163 CML patients resistant/intolerant to prior TKIs (n = 156 Ph+ CP CML, n = 4 Ph+ AP CML, n = 3 Ph-neg./BCR-ABL1+ CML) received bosutinib 500 mg once daily (starting dose). As of ≥1 yr after last enrolled patient (median treatment duration 23.7 mo), 56.4% of Ph+ CP CML patients remained on bosutinib. Primary endpoint of cumulative confirmed major cytogenetic response (MCyR) rate by 1 yr was 75.8% in Ph+ CP CML patients after one or two prior TKIs and 62.2% after three prior TKIs. Cumulative complete cytogenetic response (CCyR) and major mol. response (MMR) rates by 1 yr were 80.6% and 70.5%, resp., in Ph+ CP CML patients overall. No patient progressed to AP/BP on treatment. Across all patients, the most common treatment-emergent adverse events were diarrhea (87.7%), nausea (39.9%), and vomiting (32.5%). The majority of patients had confirmed MCyR by 1 yr and MMR by 1 yr, further supporting bosutinib use for Ph+ CP CML patients resistant/intolerant to prior TKIs. The experimental process involved the reaction of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile(cas: 380843-75-4).Recommanded Product: 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile
The Article related to human bosutinib chronic myeloid leukemia pretreatment, Pharmacology: Effects Of Cardiovascular, Hematologic, and Renal Drugs and other aspects.Recommanded Product: 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile
Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics